Pfizer CEO Albert Bourla on Monday claimed the pharmaceutical giant will be able to provide Seagen’s cancer medication
“We can add value to what Seagen is bringing,” Bourla said in a CNBC interview. “It’s more or less a situation like when mRNA was in our hands.
“With our scale, with our capabilities, this is the same here,” the CEO added further.
According to Seagen’s website, ADCs use antibodies to deliver small molecule medications directly to a tumour site
mRNA technology is employed in Covid vaccinations to deceive the human immune system into producing antibodies against the virus.